

# PUBLIC AND SCIENCE POLICY COMMITTEES MEETING AGENDA

Wednesday, June 28, 2023, 12:00 – 2:00 p.m. ET Foley & Lardner LLP 6<sup>th</sup> Floor Conference Room 3000 K Street NW, Washington, DC 20007

Zoom link: https://us02web.zoom.us/j/88076318288?pwd=cUV2aGhzY2JzRlRvenh4ci9lNVQxUT09

Meeting ID: 880 7631 8288 / Passcode: 225190

# 12:00 p.m. ET Welcome & Introduction

#### **Edward Abrahams**

President

Personalized Medicine Coalition

# 12:05 p.m. ET Business Meeting

#### Cynthia A. Bens

Senior Vice President, Public Policy Personalized Medicine Coalition

- Public Policy Updates
  - Congressional Activities
    - Congressional Personalized Medicine Caucus
    - Precision Medicine Answers for Kids Today Act (bill text from previous Congress)
    - Right Drug Dose Now Act of 2023 (bill text) and the Pharmacogenomics Education and Research Act (bill text)
      - PMC updated <u>support letter</u> (April 20, 2023)
    - FY 2024 appropriations for FDA and NIH
      - PMC House and Senate <u>testimonies</u>
      - Ad Hoc Group for Medical Research <u>sign-on letter</u> for NIH funding (March 14, 2023)



- S. 1000/H.R. 2377: Saving Access to Laboratory Services Act (SALSA)
  - ACLA <u>sign-on letter</u> (May 22, 2023)
- Access to Genetic Counselor Services Act (<u>factsheet</u>)
- Artificial intelligence and machine learning (AI/ML)

# 12:30 p.m. ET Advancing Personalized Medicine in Congress

#### Lucas Lam

Health Legislative Assistant
Office of Congressman Eric Swalwell (CA-15)
U.S. House of Representatives

# 1:00 p.m. ET Business Meeting (cont'd)

# Cynthia A. Bens

Senior Vice President, Public Policy Personalized Medicine Coalition

# Public Policy Updates (cont'd)

#### Regulation

- Trade-Related Aspects of Intellectual Property Rights (TRIPS) waiver proposals
  - PMC comment letter (May 5, 2023)
- FDA <u>rulemaking</u> on laboratory-developed tests (LDTs)
- FDA <u>final guidance</u> on *Oncology Drug Products Used with Certain In Vitro Diagnostic Tests: Pilot Program*

#### Coverage and Reimbursement

- Implementation of Medicare drug price negotiation under the Inflation Reduction Act (IRA)
  - PMC <u>comment letter</u> (April 18, 2023)
- Ways and Means Health Subcommittee Hearing on Policies That Inhibit Innovation and Patient Access
  - PMC statement for the record (May 23, 2023)
- CMS proposed rule on Transitional Coverage for Emerging Technologies (comments due August 28, 2023)



- CMS payments for CAR T-cell therapies under the Inpatient Prospective Payment Systems (IPPS) proposed rule for FY 2024
  - PMC <u>comment letter</u> (June 9, 2023)

# Daryl Pritchard, Ph.D.

Senior Vice President, Science Policy Personalized Medicine Coalition

- Science Policy Updates
  - A Research Program for Advancing Personalized Medicine in 2023 (support opportunities available)
    - Study No. 1: "Payer Perspectives and Policies on Personalized Medicine:
       A Landscape Analysis" (Parts I and II)
  - o FDA <u>Draft Guidance</u> on *Pharmacogenomic Data Submissions* 
    - PMC <u>comment letter</u> (June 20, 2023)
  - Institute for Clinical and Economic Review (ICER)'s <u>2023 Value Assessment</u> <u>Framework Proposed Changes</u> (comments due June 30, 2023)
  - Working Group Updates
    - Pharmacogenomics (PGx) Working Group
    - Health Data Working Group
- 1:50 p.m. ET New Business
- 2:00 p.m. ET Conclusion
  - Upcoming Public and Science Policy Committee Meetings
    - o September 27, 2023, 12:00 2:00 p.m. ET
    - o December 14, 2023, 12:00 2:00 p.m. ET